Proposal for Joint Research & Development of Uterine Sarcoma Therapeutics

We are seeking collaborative partners for the non-clinical and clinical development of uterine sarcoma drugs that are inhibitors of cell cycle-related genes CDK1, CDK2, CHEK1, CHEK2, Aurora Kinase B, PLK1, or TTK (Mps1).

Advantages

  • New therapeutic target for uterine sarcoma
  • Expanding the application of cell cycle-related gene inhibitors to uterine sarcoma

Background

  • Uterine sarcoma is a generic term for diseases such as uterine leiomyosarcoma and adenosarcoma, and is a rare cancer with an extremely poor prognosis.
  • Existing drugs recently approved for malignant soft tissue tumors (sarcomas and lipomas), such as trabectedin (inhibition of transcriptional function), pazopanib (inhibition of angiogenesis), and eribulin (inhibition of microtubule growth), have been clinically applied to uterine sarcoma, but have not led to dramatic improvement in prognosis.

Current Stage

  • We comprehensively analyzed the genes highly expressed in uterine sarcoma and identified a group of cell cycle-related molecules (CDK1, CDK2, CHEK1, CHEK2, Aurora Kinase B, PLK1, and TTK (Mps1)) as new candidate targets for uterine sarcoma.
  • We found that several inhibitors of this group of molecules dramatically inhibited the growth of uterine sarcoma cells (100-1000 fold IC50 compared to the aforementioned pazopanib).
  • In addition, animal studies confirmed the inhibitory effect of these inhibitors on uterine sarcoma growth. (data not shown)

Principal Investigator

Dr. Akira YOKOI (Tokai National Higher Education and Research System Nagoya University)

Suggestion for Next Step

  • We would like to conduct clinical research or investigator-initiated clinical trials in collaboration with pharmaceutical companies/biotech companies.
  • We would like to ask for your cooperation in providing us with your inhibitors.

Product No. BK-03896

Medicine

Published

Inquiry Form

Your Name (*Required)

E-Mail Address (*Required)

Company Name

Message

Following submission of your inquiry

We will contact you shortly to discuss confidentiality, materials transfer, evaluation steps, and licensing opportunities.

<Notice>

Our support is provided free of charge.
The information submitted on this form is for business development use only.

About Bionauts.jp Tech Manage Corp.
Copyright © Tech Manage Corp. All Rights Reserved.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.